We recently reported that ER-α36 mediates the agonist activity of tamoxifen by activation of the MAPK/ERK and PI3K/AKT signaling pathways in endometrial cancer cells that lack expression of ER-α66 [28]. Here, AKT1 is linked to endometrial cancer.